# Immune Effects

***

Boswellia/AKBA's immune activity is not simply "anti-inflammatory." It is a **selective inflammatory re-programmer** — suppressing the chronic, tumour-promoting inflammatory signals that help cancer survive and evade immune clearance, while preserving or supporting the acute immune responses required for immune cells to recognise and kill tumour cells. Understanding *which* mediators it affects, and *why that matters* in the anti-tumour immune cycle, is what makes this compound genuinely interesting beyond its direct anti-cancer mechanisms.

***

### The Two Faces of Inflammation in Cancer <a href="#the-two-faces-of-inflammation-in-cancer" id="the-two-faces-of-inflammation-in-cancer"></a>

Before naming the specific mediators, the framework matters. Chronic low-grade inflammation driven by NF-κB, COX-2, and 5-LOX creates a tumour microenvironment (TME) that actively suppresses the immune system's ability to kill cancer cells. It does this by:

* Recruiting and polarising **tumour-associated macrophages (TAMs)** toward an M2 (immunosuppressive) phenotype
* Elevating **IL-6 and IL-10**, which suppress cytotoxic T cell and NK cell activity
* Driving **TNF-α** at chronic low levels, which paradoxically promotes tumour survival rather than tumour death at sustained sub-acute concentrations
* Producing **PGE2** (prostaglandin E2, via COX-2), which directly suppresses NK cell and T cell function in the TME

AKBA's suppression of NF-κB, COX-2, 5-LOX, and the downstream mediators these pathways produce directly dismantles each of these immunosuppressive mechanisms.

***

### Specific Inflammatory Mediators Suppressed by AKBA <a href="#specific-inflammatory-mediators-suppressed-by-akba" id="specific-inflammatory-mediators-suppressed-by-akba"></a>

#### **TNF-α (Tumour Necrosis Factor-alpha)**

* **Suppressed** by AKBA in a concentration-dependent manner — confirmed by ELISA assay at 2.5, 5, and 10 μM (P < 0.001 for all concentrations).
* Also confirmed at the mRNA level by qPCR, showing AKBA suppresses TNF-α gene transcription, not just protein secretion.
* **Why it matters in cancer:** Chronic TNF-α in the TME supports tumour cell survival via NF-κB pro-survival signalling and promotes immunosuppressive M2 macrophage polarisation. AKBA breaks this cycle.

#### **IL-1β (Interleukin-1 beta)**

* **Suppressed** concentration-dependently at the protein and mRNA levels (P < 0.001)
* **Why it matters in cancer:** IL-1β drives VEGF-mediated angiogenesis, promotes epithelial-to-mesenchymal transition (EMT), and creates an inflammatory TME that suppresses cytotoxic T cell infiltration. It is particularly elevated in pancreatic cancer, colorectal cancer, and breast cancer. Its suppression by AKBA simultaneously reduces both tumour-promoting inflammation and immune evasion signals.

#### **IL-6 (Interleukin-6)**

* **Suppressed** concentration-dependently at protein (ELISA) and gene expression (qPCR) levelpmc.ncbi.nlm.nih+1
* **Why it matters in cancer:** IL-6 is one of the most well-documented drivers of immune evasion in cancer. It activates STAT3 in tumour cells (driving proliferation and survival), promotes M2 macrophage polarisation, suppresses dendritic cell maturation, and inhibits cytotoxic T lymphocyte (CTL) differentiation. IL-6 is chronically elevated in glioblastoma, breast, ovarian, colorectal, and prostate cancer and correlates with worse prognosis. AKBA's suppression of both IL-6 and STAT3 (via PI3K/Akt inhibition) provides dual-pathway blockade of this axis.

#### **COX-2 → PGE2 (Prostaglandin E2)**

* **COX-2 gene expression was suppressed** at the mRNA level by AKBA, concentration-dependently (P < 0.001)
* **PGE2 protein levels were directly suppressed** by AKBA (confirmed by ELISA)
* **Why it matters in cancer:** PGE2 is arguably the single most immunosuppressive lipid mediator in the TME. It directly suppresses NK cell cytotoxicity, impairs dendritic cell function, drives regulatory T cell (Treg) expansion, and promotes M2 macrophage polarisation. Every major immunosuppressive arm of the TME is partly COX-2/PGE2 driven. AKBA's dual suppression of COX-2 gene expression and PGE2 protein is therefore among its most clinically significant immune contributions.pmc.ncbi.nlm.nih+1

#### **iNOS (Inducible Nitric Oxide Synthase)**

* **Gene expression suppressed** by AKBA at mRNA level (P < 0.001)\[[pmc.ncbi.nlm.nih](https://pmc.ncbi.nlm.nih.gov/articles/PMC8986374/)]​
* **Why it matters in cancer:** iNOS-derived nitric oxide (NO) at high concentrations in the TME has complex effects — including suppression of T cell and NK cell function, promotion of tumour blood vessel formation, and contribution to genomic instability in tumour cells. Chronic iNOS-driven NO is immunosuppressive and pro-tumour. Its suppression removes a further source of TME-driven immune evasion.

#### **IFN-γ (Interferon-gamma)**

* AKBA **reduces elevated IFN-γ** in the context of LPS-induced acute systemic inflammation.
* **Why this requires careful interpretation:** IFN-γ is the primary activating cytokine for cytotoxic immune responses against cancer (it activates NK cells, CTLs, and M1 macrophages). Its reduction by AKBA in *hyper-inflammatory* contexts reflects appropriate immune tempering rather than immunosuppression of the anti-tumour response. In a chronic TME context, IFN-γ production by NK cells and CTLs is often already suppressed by the IL-6/PGE2/IL-10 environment — AKBA's net effect of removing those suppressors is pro-IFN-γ in the anti-tumour context. This nuance is important: AKBA is not a broad IFN-γ suppressor; it is an acute inflammatory modulator.

#### **IL-10 (Interleukin-10)**

* AKBA **increases IL-10** compared to LPS-treated inflammatory conditions.
* **Why it matters:** In a chronic TME context, elevated IL-10 sounds counterintuitive (IL-10 is immunosuppressive). However, in the specific context of resolving acute LPS-driven hyperinflammation, IL-10 rise is part of appropriate immune resolution. In the TME, the balance is complex — but the increase here reflects AKBA's capacity to shift the immune microenvironment from pathological chronic inflammation toward resolved, regulated inflammation that creates space for effective anti-tumour immune activity rather than exhausted immune cells unable to function in a chronically inflamed environment.

#### **LTB4 (Leukotriene B4) via 5-LOX**

* AKBA directly inhibits 5-LOX with an **IC50 of 1.5 μM** in human neutrophils (non-redox, non-competitive inhibition) — the most potent 5-LOX inhibitory activity of all boswellic acids.
* **Important pharmacokinetic caveat:** In the presence of albumin (10 mg/mL), 11-keto boswellic acid's 5-LOX inhibition was abolished in whole blood assays — attributed to >95% albumin binding. This means bioavailability and formulation quality directly determine whether 5-LOX inhibition translates in vivo.
* **Why it matters in cancer:** LTB4 is a potent chemoattractant that recruits immunosuppressive myeloid cells and mast cells into the TME. It promotes tumour angiogenesis and has direct proliferative effects on certain cancer cell types (prostate, colorectal). 5-LOX inhibition by AKBA is a mechanism curcumin and polydatin do not share — it is a genuinely unique contribution to the anti-inflammatory combination stack.

***

### How This Translates to the Anti-Tumour Immune Cycle <a href="#how-this-translates-to-the-anti-tumour-immune-cycl" id="how-this-translates-to-the-anti-tumour-immune-cycl"></a>

The cancer-immunity cycle — from tumour antigen release through to CTL-mediated cancer cell killing — fails at multiple points in established tumours. Here is where AKBA's specific mediator suppression intervenes:

| Immune Cycle Step                       | What Normally Fails in Tumours                                                                       | AKBA's Contribution                                                                                                |
| --------------------------------------- | ---------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------ |
| Antigen presentation by dendritic cells | IL-6 and PGE2 suppress DC maturation and MHC-II expression                                           | COX-2/PGE2 and IL-6 suppression allows DCs to mature and present tumour antigens more effectively                  |
| T cell priming and activation           | IL-6/STAT3 axis suppresses CTL differentiation; Tregs expand under PGE2 influence                    | IL-6 and PGE2 reduction supports CTL priming; Treg-promoting environment reduced                                   |
| NK cell tumour killing                  | PGE2, IL-10, and TAM-derived TGF-β suppress NK cytotoxicity; tumour cells downregulate NKG2D ligands | PGE2/COX-2 suppression removes a primary NK cell inhibitor in the TME                                              |
| Macrophage polarisation                 | TAMs are driven to M2 (tumour-promoting) phenotype by IL-6, IL-10, PGE2                              | AKBA modulates macrophage polarisation toward less immunosuppressive phenotype via NF-κB and IL-6/PGE2 suppression |
| Tumour immune evasion                   | Chronic TNF-α, IL-1β and NF-κB drive tumour survival and PD-L1 upregulation                          | NF-κB/TNF-α/IL-1β suppression reduces pro-survival and immune checkpoint signalling in tumour cells                |

***

### Macrophage and Dendritic Cell Effects <a href="#macrophage-and-dendritic-cell-effects" id="macrophage-and-dendritic-cell-effects"></a>

**Macrophage polarisation:** AKBA modulates macrophage inflammatory behaviour, confirmed in a 2024 CNS Neuroscience & Therapeutics study showing AKBA modulates macrophage polarisation and neuroinflammation. In the context of the TME, where M2-polarised TAMs are a primary driver of immune evasion and treatment resistance, the removal of key M2-polarising signals (IL-6, IL-10 at pathological levels, PGE2) by AKBA represents a meaningful shift toward immune competence.

**Dendritic cells:** AKBA inhibits the secretion of pro-inflammatory cytokines (TNF-α, IL-12, IL-23, IL-22, IL-1β) by mature dendritic cells in hyperinflammatory contexts — while the broader evidence suggests that by removing chronic TME inflammatory suppression, DC maturation and antigen presentation capacity is net-improved in the tumour context. This apparent paradox (AKBA reduces DC cytokine output in hyperinflammatory conditions but supports DC function in a tumour context) reflects the same context dependence seen across all its mechanisms.

***

### Overall Immune Impact: SELECTIVE INFLAMMATORY RE-PROGRAMMER <a href="#overall-immune-impact-selective-inflammatory-re-pr" id="overall-immune-impact-selective-inflammatory-re-pr"></a>

| Parameter        | AKBA Effect                                           | Immune Consequence                                                              |
| ---------------- | ----------------------------------------------------- | ------------------------------------------------------------------------------- |
| TNF-α            | ↓ Concentration-dependent (confirmed by ELISA + qPCR) | Reduces TME pro-survival and M2 polarisation signals                            |
| IL-1β            | ↓ Concentration-dependent (confirmed by ELISA + qPCR) | Reduces angiogenesis, EMT, and T cell infiltration suppression                  |
| IL-6             | ↓ Concentration-dependent (confirmed by ELISA + qPCR) | Removes primary CTL and DC suppressor; reduces STAT3-driven immune evasion      |
| PGE2             | ↓ Direct COX-2 gene + PGE2 protein suppression        | Removes primary NK cell and Treg-promoting mediator in the TME                  |
| iNOS/NO          | ↓ mRNA level confirmed                                | Reduces immunosuppressive NO and genomic instability                            |
| LTB4 (via 5-LOX) | ↓ IC50 1.5 μM in neutrophils                          | Reduces myeloid immune suppressor and mast cell recruitment to TME              |
| IL-10            | ↑ In hyperinflammatory contexts                       | Resolves pathological inflammation; creates space for effective immune activity |

***

**References for Immune Effects**

* AKBA prevents inflammation via suppression of TNF-α, IL-1β, IL-6, PGE2, COX-2 and iNOS — PMC 2022 — <https://pmc.ncbi.nlm.nih.gov/articles/PMC8986374/>
* AKBA suppresses colitis-associated colorectal cancer and reduces TNF-α, IFN-γ, IL-12p70, IL-1β; increases IL-10 — PMC 2025 — <https://pmc.ncbi.nlm.nih.gov/articles/PMC12308244/>
* From bench to bedside: boswellic acids in anti-inflammatory therapy — 5-LOX IC50, NF-κB mechanism, cytokine panel — PMC 2025 — <https://pmc.ncbi.nlm.nih.gov/articles/PMC12669112/>
* AKBA modulates macrophage polarisation — CNS Neuroscience & Therapeutics, 2024 — <https://onlinelibrary.wiley.com/doi/full/10.1111/cns.14642>
* AKBA inhibits cytokine secretion by dendritic cells — <https://www.sciencedirect.com/science/article/abs/pii/S0024320518303126>
* T cells, NK cells, and TAMs in anti-tumour immune cycles — Yang et al., 2023 — <https://pubmed.ncbi.nlm.nih.gov/37457707/>
* NK cell anti-tumour activity and macrophage interaction — Frontiers in Immunology, 2025 — <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1656925/full>

### Jump to another Boswellia page

**Core pages**

* [Boswellia in Oncology Overview](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms.md)
* [Boswellia Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type.md)

**Mechanism deep dives**

* [Redox Dual Action](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action.md)
* [NRF2 Impact](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact.md)
* [Ferroptosis Findings](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md)

**Practical pages**

* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism.md)
* [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations.md)
* [Hydroxychloroquine + Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia.md)
* [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing.md)
* [Sourcing Quality Boswellia](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia.md)

**Cancer-type pages**

* [Glioblastoma & Brain Tumours](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer.md)
* [Colorectal Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer.md)
* [Pancreatic Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer.md)
* [Prostate Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types.md)

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.